MARLBOROUGH, Mass.,
May 11, 2016 /PRNewswire/ -- Hologic,
Inc. (Nasdaq: HOLX) announced today that the MyoSure®
suite of gynecologic surgical products is expanding to include the
MyoSure REACH device. The MyoSure REACH device confronts the
challenge of hard-to-reach uterine pathology by enabling access to
the upper third of the uterine cavity1.
"The ability to remove hard-to-reach intrauterine pathology is
an important enhancement for the MyoSure system, and it
demonstrates Hologic's dedication to women's health," said
Edward Evantash, M.D., Medical
Director and Vice President of Medical Affairs, Hologic. "The
MyoSure REACH device offers the benefits of the current device,
plus expanded capabilities to remove pathology in the upper third
of the uterine cavity."
The MyoSure tissue removal system is designed to offer a
simple and quick solution for women with polyps and fibroids, which
often cause abnormal uterine bleeding (AUB). AUB is estimated to
affect 11 to 13 percent of reproductive-age women and nearly 24
percent of women ages 36 to 402. The MyoSure REACH
device features a shortened distance from the distal tip to the
cutting window of less than 1 millimeter. When compared to
the predecessor device, the new design has been shown to get three
times closer to the uterine wall and removes 25 percent more tissue
in a simulated bench top model3. The new product will be
displayed and available for demonstrations for the first time at
the American College of Obstetricians and Gynecologists (ACOG)
Annual Clinical and Scientific Meeting in Washington, D.C. from May 14 to 17. Other devices in the MyoSure
suite of products include the MyoSure, MyoSure® XL, and MyoSure®
LITE devices.
"The MyoSure REACH device helps physicians better meet the needs
of their patients by providing them an efficient and effective
solution for pathology removal," said Tom
O'Neill, Hologic's Division President, GYN Surgical
Solutions. "The MyoSure REACH device is an exciting addition to
Hologic's suite of gynecologic solutions, which are quick and
effective for physicians and patients."
Hologic to Offer Comprehensive Educational Opportunities and
a Mobile Broadcast Studio at Booth #600 during ACOG Meeting
At ACOG, Hologic is partnering with ReachMD to feature a mobile
broadcast studio that will record and broadcast educational
interviews and sessions from its booth. These expert interviews
will address a full range of women's health topics, including
breast health, abnormal uterine bleeding, sexually transmitted
infections, and cervical cancer screening. Interviews will take
place on the half-hour on Sunday, May
15 from 10 a.m. to 5 p.m., and
on Monday, May 16 from 10 a.m. to 5 p.m.
A full listing of activities can be viewed at the Hologic Booth
(#600), including:
- Introduction to the MyoSure® REACH device
- Evidence-based discussion on cervical cancer screening
- NAAT vs. wet mount for STI screening
Also available at the Hologic booth:
- Breast cancer patient education tools
- Genius™ 3D MAMMOGRAPHY™, the number one
OB/GYN-referred breast tomosynthesis exam4, which is
more accurate5,6 and detects breast cancer 15 months
earlier7 than conventional exams
- Dr. Linda Greer, Medical
Director of HonorHealth Breast Health and Research Center and
co-author of the groundbreaking study "Breast Cancer Screening
Using Tomosynthesis in Combination with Digital Mammography,"
published in the Journal of the American Medical Association
(JAMA). Dr. Greer will analyze 2D versus 3D™
MAMMOGRAPHY images and review patient cases
- Educational material surrounding National Osteoporosis Month in
May. Additional prevention tips and resources can be found at
www.boneawareness.com
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic, The Science of Sure, 3D Mammography, Genius, MyoSure,
and associated logos are trademarks and/or registered trademarks of
Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All
other trademarks, registered trademarks, and product names are the
property of their respective owners.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact
Michael
Watts
858.410.8588
Michael.watts@hologic.com
1 Di Spiezio Sardo A, Calagna G, Guida M, Perino
A, Nappi C. Hysteroscopy and treatment of uterine polyps. Best
Pract Res Clin Obstet Gynaecol. 2015;29:908-919.
2 Primary Care Management of Abnormal Uterine
Bleeding. Agency for Health Care Research and Quality website
http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1431&pageaction=displayproduct.
Updated March 21, 2013. Accessed
April 25, 2016.
3 Based on internal bench testing that measured
average relative height change of simulated 2-cm diameter tissue
resected from a uterine model by 11 surgeon users
4 ProVoice Survey conducted by AlphaImpactRx
5 Friedewald SM, Rafferty EA, Rose SL, et al.
Breast cancer screening using tomosynthesis in combination with
digital mammography. JAMA. 2014;311(24):2499-2507.
6 Rose SL, Tidwell AL, Bujnoch LJ, Kushwaha AC,
Nordmann AS, Sexton R. Implementation of breast tomosynthesis in a
routine screening practice: an observational study. AJR Am J
Roentgenol. 2013;200(6):1401- 1408
7 McDonald ES, Oustimov A, Weinstein SP,
Synnestvedt MB, Schnall M, Conant EF. Effectiveness of digital
breast tomosynthesis compared with digital mammography: outcomes
analysis from 3 years of breast cancer screening. JAMA
Oncol. 2016:E1-E7.
http://oncology.jamanetwork.com/article.aspx?articleid=2491465.
Accessed March 2, 2016.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-introduces-the-myosure-reach-device-to-help-physicians-access-the-hard-to-reach-upper-third-of-the-uterine-cavity-300266639.html
SOURCE Hologic, Inc.